Sugi Predict

Sugi Predict / Compounds / SCHEMBL357993

SCHEMBL357993

SCHEMBL357993

Cc1c[nH]c2ncnc(Cl)c12

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.61
▸ AKT1 P31749 8/20 0.44
▸ TRPA1 O75762 1/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.43
▸ LIMK1 P53667 4/20 0.40
▸ ROCK2 O75116 3/20 0.40
▸ AURKA O14965 1/20 0.39
▸ KHK P50053 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ BRAF P15056 1/20 0.38
▸ TNNI3K Q59H18 1/20 0.38
▸ NOTUM Q6P988 1/20 0.36
▸ ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7027653 0.79 CHEK1 (0.56) CHEK1AKT1TRPA1IRAK4ROCK2
SCHEMBL1598149 0.79 CHEK1 (0.66) CHEK1AKT1TRPA1AURKABRAF
SCHEMBL31329069 0.79 CHEK1 (0.66) CHEK1AKT1TRPA1AURKABRAF
SCHEMBL9967152 0.79 AKT1 (0.46) CHEK1AKT1TRPA1IRAK4LIMK1
SCHEMBL10259826 0.78 AKT1 (0.45) CHEK1AKT1TRPA1IRAK4LIMK1
SCHEMBL2323682 0.78 CHEK1 (0.63) CHEK1AKT1TRPA1AURKANOTUM
SCHEMBL153752 0.78 CHEK1 (0.63) CHEK1AKT1TRPA1IRAK4AURKA
SCHEMBL2321413 0.76 CHEK1 (0.61) CHEK1AKT1TRPA1IRAK4LIMK1
SCHEMBL5019486 0.76 CHEK1 (0.61) CHEK1AKT1TRPA1IRAK4LIMK1
SCHEMBL61206 0.76 CHEK1 (1.00) CHEK1AKT1TRPA1AURKANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 — — EP disclosed
US-12391695-B2 PRMT5 inhibitors LUPIN LIMITED (IN) 2025-08-19 — — US disclosed
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2025-06-12 — — US disclosed
US-20250134869-A1 Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides PFIZER INC (US) 2025-05-01 — — US disclosed
EP-3833668-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-19 — — EP disclosed
WO-2025019585-A1 KINASE INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-01-23 — — WO disclosed
US-12173026-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-12-24 — — US disclosed
CN-112805006-B PRMT5 inhibitors 默沙东有限责任公司 2024-09-24 — — CN disclosed
US-12077533-B2 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides PFIZER INC. (US) 2024-09-03 — — US disclosed
CN-118530261-A Fused bicyclic derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2024-08-23 — — CN disclosed
US-6395733-B1 ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS PFIZER INC 2002-05-28 — — US disclosed
EP-0496617-B1 Adenosine kinase inhibitors METABASIS THERAPEUTICS INC (US) 1999-12-01 — — EP disclosed
EP-0831829-A4 HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES PFIZER (US) 1998-11-25 — — EP disclosed
EP-0831829-A1 HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES PFIZER INC. (US) 1998-04-01 — — EP disclosed
US-5646128-A TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS GENSIA, INC. (US) 1997-07-08 — — US disclosed
CN-1141298-A Pyrimidine-fused heterocyclic compound anti-cancer agents PFIZER (US) 1997-01-29 — — CN disclosed
WO-1996040142-A1 HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES PFIZER INC. (US) 1996-12-19 — — WO disclosed
WO-1994017803-A9 ADENOSINE KINASE INHIBITORS — 1994-09-29 — — WO disclosed
WO-1992012718-A1 ADENOSINE KINASE INHIBITORS GENSIA, INC. (US) 1992-08-06 — — WO disclosed
EP-0496617-A1 Adenosine kinase inhibitors GENSIA, INC. (US) 1992-07-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION KMT5A, KMT5B, KMT5C CHEK1 1887/4885AKT1 830/4885TRPA1 4787/4885
US-12077533-B2 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides ACR, PKD2, PGA5 CHEK1 718/4885AKT1 3455/4885TRPA1 98/4885
US-12391695-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 CHEK1 1297/4885AKT1 1148/4885TRPA1 4832/4885
US-12173026-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 CHEK1 642/4885AKT1 598/4885TRPA1 4200/4885
US-20250134869-A1 Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides JAK2, JAK3, JAK1 CHEK1 339/4885AKT1 690/4885TRPA1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.